The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

2.

A study outlines the need for policies that enhance cancer patients' autonomy and information.

3.

A study suggests that screening for liver cancer is beneficial for patients with cirrhosis.

4.

Prostate cancer screening program beneficial in top decile of polygenic risk score

5.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot